Prognostic significance of baseline C-reactive protein/albumin ratio for long-term outcomes in advanced gastric cancer under immunochemotherapy

Table 4 Univariate and multivariate analyses of prognostic factors for overall survival

Variables	Univariate		Multivariate
	P value	HR (95%CI)	P value	HR (95%CI)
PD-L1 expression (CPS < 5 vs CPS ≥ 5)	< 0.001	0.34 (0.23-0.49)	< 0.001	0.45 (0.30-0.66)
MMR status (pMMR vs dMMR)	< 0.001	0.22 (0.12-0.42)	0.001	0.34 (0.18-0.64)
CAR (high vs low)	< 0.001	0.45 (0.31-0.64)	< 0.001	0.51 (0.35-0.73)
Sex (male vs female)	0.595	0.91 (0.63-1.31)
Age (≥ 60 vs < 60), years	0.702	1.07 (0.74-1.55)
BMI (< 25 vs ≥ 25), kg/m2	0.408	0.82 (0.51-1.31)
CEA (< 3 vs ≥ 3), ng/mL	0.644	1.09 (0.76-1.57)
CA199 (< 37 vs ≥ 37), ng/mL	0.544	1.12 (0.78-1.62)
ECOG (0 vs 1)	0.326	1.21 (0.83-1.76)
Staging (III vs IV)	< 0.001	2.69 (1.83-3.94)	0.012	1.70 (1.12-2.58)
Differentiation (poorly/undifferentiated vs medium/high)	0.131	0.59 (0.30-1.17)
Site (gastric and esophageal binding vs stomach)	0.823	1.05 (0.70-1.57)
Peritoneal metastasis (no vs yes)	< 0.001	2.02 (1.41-2.91)	0.005	1.73 (1.17-2.54)
Liver metastasis (no vs yes)	0.064	1.50 (0.98-2.29)
EBV status (infect vs no-infect)	0.196	0.60 (0.28-1.30)
Neutrophil	0.178	1.05 (0.98-1.12)
Lymphocyte	0.368	0.87 (0.65-1.17)

HR: Hazard ratio; CI: Confidence interval; PD-L1: Programmed death-ligand 1; CPS: Combined positive score; MMR: Mismatch repair; pMMR: Proficient mismatch repair; dMMR: Deficient mismatch repair; CAR: C-reactive protein/albumin ratio; BMI: Body mass index; CEA: Carcinoembryonic-antigen; CA199: Carbohydrate antigen 199; ECOG: Eastern Cooperative Oncology Group; EBV: Epstein-Barr virus.